Preventing nausea from ADC cancer treatment
Part of Digestive system clinical trials.
This study tests whether a combination of two medicines (fosrolapitant and palonosetron) can prevent nausea and vomiting caused by antibody-drug conjugate therapy, a type of targeted cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with a malignant (cancerous) tumor
- You have never received an antibody-drug conjugate (ADC) before and will be getting your first dose as part of this study
- You are expected to live at least 3 more months
- You are able to do daily activities with little or no help (ECOG 0 or 1)
- You have adequate bone marrow, kidney, and liver function (confirmed by blood tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two medications (fosrolapitant and palonosetron) to prevent severe nausea and vomiting in patients with esophageal or lung cancer who are receiving chemotherapy combined with immunotherapy. If the medications work well, they could help patients feel better during treatment and complete their cancer care more comfortably.
This study tests if two medicines given together, fosaprepitant and palonosetron, can prevent nausea and vomiting caused by strong chemotherapy given over several days. It's for people who have never had chemo before and are about to start a multi-day treatment for a solid tumor.
This trial tests whether a combination of two anti-nausea drugs (fosrolapitant and palonosetron) can better prevent nausea and vomiting caused by Trastuzumab Rezetecan. If you are starting this cancer treatment, you may be able to join.
This trial tests two anti-nausea medications, Rolapitant and Palonosetron, to see how well they prevent nausea and vomiting in people with lung cancer who are receiving both chemotherapy and radiation. The study aims to help patients manage these side effects better during treatment.
This trial studies whether palonosetron helps prevent nausea and vomiting caused by chemotherapy that has a moderate risk of vomiting. It may help you feel more comfortable during chemo and avoid treatment interruptions from severe nausea.
This study tests whether the medication NEPA (Netupitant and Palonosetron) can prevent nausea and vomiting in people who have had surgery for liver, gallbladder, or pancreatic cancer. It may help those who want to avoid post-surgery sickness.
Hear when a new Nausea and Vomiting Induced by Antibody-drug Conjugates (ADCs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.